Radiation Oncology

The Radiation Oncology Department at SGM Cancer Hospital aspires to provide the most advanced and precise cancer care with a multidisciplinary evidence guided approach. Using cutting-edge technology and clinical expertise, we utilize ionizing radiation to destroy cancer cells and shrink tumours. Our advanced Varian VitalBeam linear accelerator can provide highly conformal radiotherapy that targets precisely the tumour and spares surrounding healthy tissue. Our team includes Radiation oncologists who offer clinical care, design treatment, outline and monitor patients during radiotherapy; Medical physicists are responsible for radiotherapy commissioning, developing complex and precise clinical plans for treatment and ensuring radiation safety for patients and staff; Radiation technologists who operate machines and deliver radiotherapy.

Advanced Equipments

  • Varian VitalBeam linear accelerator with Eclipse treatment planning system


    • Configuration of three photon and six electron energies
    • Maestro control system orchestrates dose, motion and imaging to deliver fast and efficient treatment
    • Built in accuracy checks performed every 10 ms during treatment
    • Integrated workflow with Eclipse and ARIA information system
    • Eclipse capable of wide range of planning options including RapidArc planning
    • Knowledge based RapidPlan and SmartSegmentation
  • Varian GammaMedplus iX brachytherapy afterloader machine with High dose rate Iridium-192 source and BrachyVision treatment planning system


    • Increased safety using fixed length treatment distance
    • Wide range of treatment accessories suitable for CT/MR imaging
  • ARIA Oncology Information System


  • RapidArc / Volumetric Modulated Arc Therapy (VMAT)

  • Intensity Modulated Radiation Therapy (IMRT)

  • Image Guided Radiation Therapy (IGRT)

  • Stereotactic Radio-Surgery (SRS) and Stereotactic Radiotherapy (SRT)

  • Stereotactic Body Radiation Therapy (SBRT)

  • 3D Conformal Radiation Therapy (3DCRT)

  • Short course palliative radiotherapy

  • HDR Brachytherapy for intra-cavitary and interstitial applications

Our Team

Dr. Tejshri Telkhade Wadaskar

Radiation oncology

MBBS, MD (Radiation Oncology) Fellowship in Uro- Oncology ( Tata Memorial Hospital)


Dr. Tejshri Telkhade Wadaskar has diverse experience with state of art oncology institutions such as the prestigious Tata Memorial Hospital, Mumbai (2013 – 2020) where she pursued MD in Radiation Oncology and Fellowship in Uro-Radiation oncology. Thereafter, she was at Sir H. N. Reliance Foundation Hospital, Mumbai, a globally renowned oncology centre (2020-2021). Her areas of interest are Prostate, Breast, Lymphoma and Gynaecological cancer management.

Dr Tejshri Telkhade Wadaskar is passionate about raising cancer awareness and research related to optimal utilization of resources and techniques to effectively reduce cancer burden in society.


  1. Budrukkar, A., Telkhade, T., Wadasadawala, T.,(2020). A comparison of long-term clinical outcomes of accelerated partial breast irradiation using interstitial brachytherapy as per GEC-ESTRO, ASTRO, updated ASTRO, and ABS guidelines. Brachytherapy, 19(3), 337-347. doi: 10.1016/j.brachy.2020.02.011

  2. Murthy, V., Mallick, I., Gavarraju, A. Telkhade,T. (2020). Study protocol of a randomised controlled trial of prostate radiotherapy in high-risk and node-positive disease comparing moderate and extreme hypofractionation (PRIME TRIAL). 10(2), e034623. doi:10.1136/bmjopen-2019-034623

  3. Telkhade,T., Murthy,V.,(2019). Toxicity and outcomes of ultrahypofractionation with stereotactic body radiation therapy for high risk and node positive prostate cancer. Abstract, J Can Res Ther ;15:298-300

  4. Gupta, T. Telkhade, T. (2016) Intensity Modulated Radiation Therapy (IMRT) for Craniospinal-Irradiation on Helical Tomotherapy (HT): Effect of Low-Dose bath on Acute Hematologic Toxicity. Abstract, International journal of radiation oncology, biology and physics, Volume 96 Number 2S Supplement

  5. Telkhade T, Murthy V, Kanala TS, Mathew JM, Phurailatpam R, Mokal S, Chourasiya D, Panigrahi G, Krishnatry R. Safety and Efficacy of Ultra-hypofractionation in Node-positive Prostate Cancer. Clin Oncol (R Coll Radiol). 2021 Mar;33(3):172-180. doi: 0.1016/j.clon.2020.10.019. Epub 2020 Nov 16. PMID: 33214044.

  6. van Dams R, Jiang NY, Fuller DB, Loblaw A, Jiang T, Katz AJ, Collins SP, Aghdam N, Suy S, Stephans KL, Yuan Y, Nickols NG, Murthy V, Telkhade TP, Kupelian PA, Steinberg ML,Romero T, Kishan AU. Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients. Int J Radiat Oncol Biol Phys. 2021 Jan 23:S0360-3016(21)00068-7. doi:10.1016/j.ijrobp.2021.01.016. Epub ahead of print. PMID: 33493615

  7. Foerster R, Zwahlen DR, Buchali A, Tang H, Schroeder C, Windisch P, Vu E, Akbaba S, Bostel T, Sprave T, Zamboglou C, Zilli T, Stelmes JJ, Telkhade T, Murthy V. Stereotactic Body Radiotherapy for High-Risk Prostate Cancer: A Systematic Review. Cancers (Basel). 2021 Feb 12;13(4):759. doi: 10.3390/cancers13040759. PMID: 33673077; PMCID: PMC7918664.

  8. Khurud P, Krishnatry R, Telkhade T, Patil A, Prakash G, Joshi A, Pal M, Noronha V, Menon S, Bakshi G, Prabhash K, Murthy V. Impact of Adjuvant Treatment in pN3 Penile Cancer. Clin Oncol (R Coll Radiol). 2021 Oct 31:S0936-6555(21)00371-X. doi: 10.1016/j.clon.2021.10.005. PMID: 34732295.

Phy. Anurag Luharia

Radiation oncology

Medical physics and Radiological safety officer MSMRP, PGDRTT, MBA, AERB Certified RSO-L3

Enquire Now